4.7 Article

Neural Substrates of Attentional Bias for Smoking-Related Cues: An fMRI Study

Journal

NEUROPSYCHOPHARMACOLOGY
Volume 35, Issue 12, Pages 2339-2345

Publisher

SPRINGERNATURE
DOI: 10.1038/npp.2010.103

Keywords

fMRI; smoking; smoking emotional stroop; interference; interoception; memory

Funding

  1. ANT North America Inc.
  2. AstraZeneca
  3. Pfizer
  4. Abbott Laboratories
  5. Alkermes
  6. Aspect Medical Systems
  7. BioResearch
  8. BrainCells, Inc.
  9. Bristol-Myers Squibb Company
  10. Cephalon
  11. Clinical Trial Solutions
  12. LLC
  13. Eli Lilly Company
  14. Forest Pharmaceuticals Inc.
  15. Ganeden
  16. GlaxoSmithKline
  17. J & J Pharmaceuticals
  18. Lichtwer Pharma GmbH
  19. Lorex Pharmaceuticals
  20. NARSAD
  21. NCCAM
  22. NIDA
  23. NIMH
  24. Novartis
  25. Organon Inc.
  26. Organon Inc., PamLab
  27. Pfizer Inc.
  28. Pharmavite
  29. Roche
  30. Sanofi-Aventis
  31. Shire
  32. Solvay Pharmaceuticals, Inc.
  33. Synthelabo
  34. Wyeth-Ayerst Laboratories
  35. GSK
  36. Organon
  37. Varian Inc.

Ask authors/readers for more resources

Attentional bias for drug-related stimuli, as measured by emotional Stroop (ES) tasks, is predictive of treatment outcomes for tobacco smoking and other abused drugs. Characterizing relationships between smoking-related attentional bias and brain reactivity to smoking images may help in identifying neural substrates critical to relapse vulnerability. To this end, we investigated putative relationships between interference effects in an offline smoking ES task and functional MRI (fMRI) measures of brain reactivity to smoking vs neutral images in women smokers. Positive correlations were found between attentional bias and reactivity to smoking images in brain areas involved in emotion, memory, interoception, and visual processing, including the amygdala, hippocampus, parahippocampal gyrus, insula, and occipital cortex. These findings suggest that smokers with elevated attentional biases to smoking-related stimuli may more readily shift attention away from other external stimuli and toward smoking stimuli-induced internal states and emotional memories. Such attentional shifts may contribute to increased interference by smoking cues, possibly increasing relapse vulnerability. Treatments capable of inhibiting shifts to drug cue-induced memories and internal states may lead to personalized tobacco dependence treatment for smokers with high attentional bias to smoking-related stimuli. Neuropsychopharmacology (2010) 35, 2339-2345; doi: 10.1038/npp.2010.103; published online 11 August 2010

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available